Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Evaluation of 3D Printed Gelatin-Based Scaffolds with Varying Pore Size for MSC-Based Adipose Tissue Engineering.

Tytgat L, Kollert MR, Van Damme L, Thienpont H, Ottevaere H, Duda GN, Geissler S, Dubruel P, Van Vlierberghe S, Qazi TH.

Macromol Biosci. 2020 Feb 20:e1900364. doi: 10.1002/mabi.201900364. [Epub ahead of print]

PMID:
32077631
2.

Complications During Inter-Hospital Transfer of Patients with Acute Ischemic Stroke for Endovascular Therapy.

Sablot D, Leibinger F, Dumitrana A, Duchateau N, Van Damme L, Farouil G, Gaillard N, Lachcar M, Benayoun L, Arquizan C, Ibanez M, Coll F, Fadat B, Nguyen Them L, Desmond L, Allou T, Smadja P, Ferraro-Allou A, Mourand I, Dutray A, Pujol C, Tardieu M, Jurici S, Bonnec JM, Olivier N, Mas J, Costalat V, Bonafe A.

Prehosp Emerg Care. 2020 Jan 7:1-7. doi: 10.1080/10903127.2019.1695299. [Epub ahead of print]

PMID:
31750753
3.

Which Patients Require Physician-Led Inter-Hospital Transport in View of Endovascular Therapy?

Leibinger F, Sablot D, Van Damme L, Gaillard N, Nguyen Them L, Lachcar M, Duchateau N, Arquizan C, Farouil G, Ibanez M, Pujol C, Fadat B, Allou T, Coll F, Benayoun L, Mas J, Smadja P, Ferraro-Allou A, Mourand I, Dutray A, Tardieu M, Jurici S, Bonnec JM, Olivier N, Cardini S, Aptel S, Marquez AM, Dumitrana A, Costalat V, Bonafe A.

Cerebrovasc Dis. 2019;48(3-6):171-178. doi: 10.1159/000504314. Epub 2019 Nov 14.

PMID:
31726450
4.

Mechanical Recanalization after Transfer from a Distant Primary Stroke Center: Effectiveness and Future Directions.

Farouil G, Sablot D, Leibinger F, Van Damme L, Coll F, Gaillard N, Ibanez M, Smadja P, Benayoun L, Dutray A, Tardieu M, Nguyen Them L, Bonnec JM, Jurici S, Bensalah ZM, Olivier N, Desmond L, Fadat B, Bertrand JL, Mas J, Akouz A, Allou T, Mourand I, Ferraro-Allou A, Dumitrana A, Aptel S, Arquizan C, Costalat V, Bonafe A.

J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104368. doi: 10.1016/j.jstrokecerebrovasdis.2019.104368. Epub 2019 Sep 16.

PMID:
31537417
5.

Extrusion-based 3D printing of photo-crosslinkable gelatin and κ-carrageenan hydrogel blends for adipose tissue regeneration.

Tytgat L, Van Damme L, Ortega Arevalo MDP, Declercq H, Thienpont H, Otteveare H, Blondeel P, Dubruel P, Van Vlierberghe S.

Int J Biol Macromol. 2019 Nov 1;140:929-938. doi: 10.1016/j.ijbiomac.2019.08.124. Epub 2019 Aug 15.

PMID:
31422191
6.

Additive manufacturing of photo-crosslinked gelatin scaffolds for adipose tissue engineering.

Tytgat L, Van Damme L, Van Hoorick J, Declercq H, Thienpont H, Ottevaere H, Blondeel P, Dubruel P, Van Vlierberghe S.

Acta Biomater. 2019 Aug;94:340-350. doi: 10.1016/j.actbio.2019.05.062. Epub 2019 May 25.

PMID:
31136829
7.

The bumpy road to change: a retrospective qualitative study on formerly detained adolescents' trajectories towards better lives.

Van Hecke N, Vanderplasschen W, Van Damme L, Vandevelde S.

Child Adolesc Psychiatry Ment Health. 2019 Feb 25;13:10. doi: 10.1186/s13034-019-0271-6. eCollection 2019.

8.

Futile inter-hospital transfer for mechanical thrombectomy in a semi-rural context: analysis of a 6-year prospective registry.

Sablot D, Dumitrana A, Leibinger F, Khlifa K, Fadat B, Farouil G, Allou T, Coll F, Mas J, Smadja P, Ferraro-Allou A, Mourand I, Dutray A, Tardieu M, Jurici S, Bonnec JM, Olivier N, Cardini S, Damon F, Van Damme L, Aptel S, Gaillard N, Marquez AM, Nguyen Them L, Ibanez M, Arquizan C, Costalat V, Bonafe A.

J Neurointerv Surg. 2019 Jun;11(6):539-544. doi: 10.1136/neurintsurg-2018-014206. Epub 2018 Oct 16.

PMID:
30327386
9.
10.

Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study.

Masson L, Barnabas S, Deese J, Lennard K, Dabee S, Gamieldien H, Jaumdally SZ, Williamson AL, Little F, Van Damme L, Ahmed K, Crucitti T, Abdellati S, Bekker LG, Gray G, Dietrich J, Jaspan H, Passmore JS.

Sex Transm Infect. 2019 Feb;95(1):5-12. doi: 10.1136/sextrans-2017-053506. Epub 2018 Jul 17.

PMID:
30018088
11.

Use of a national identification database to determine the lifetime prognosis in cattle with necrotic laryngitis and the predictive value of venous pCO2.

Pardon B, Ribbens S, Van Damme L, Vlaminck L, Martens A, Deprez P.

J Vet Intern Med. 2018 Jul;32(4):1462-1470. doi: 10.1111/jvim.15223. Epub 2018 Jul 3.

12.

Verification of chemistry reference ranges using a simple method in sub-Saharan Africa.

De Baetselier I, Taylor D, Mandala J, Nanda K, Van Campenhout C, Agingu W, Madurai L, Barsch EM, Deese J, Van Damme L, Crucitti T.

Afr J Lab Med. 2016 Oct 17;5(1):404. doi: 10.4102/ajlm.v5i1.404. eCollection 2016.

13.

Detection of new HIV infections in a multicentre HIV antiretroviral pre-exposure prophylaxis trial.

Fransen K, de Baetselier I, Rammutla E, Ahmed K, Owino F, Agingu W, Venter G, Deese J, Van Damme L, Crucitti T; FEMPrEP study group.

J Clin Virol. 2017 Aug;93:76-80. doi: 10.1016/j.jcv.2017.03.013. Epub 2017 Mar 20.

PMID:
28351689
14.

Performance of serological and molecular tests within acute HIV infection.

Fransen K, de Baetselier I, Rammutla E, Ahmed K, Owino F, Agingu W, Venter G, Deese J, Van Damme L, Crucitti T; FEMPrEP study group.

J Clin Virol. 2017 Aug;93:81-84. doi: 10.1016/j.jcv.2017.03.010. Epub 2017 Mar 21.

PMID:
28351688
15.

The unique relation of childhood emotional maltreatment with mental health problems among detained male and female adolescents.

Vahl P, van Damme L, Doreleijers T, Vermeiren R, Colins O.

Child Abuse Negl. 2016 Dec;62:142-150. doi: 10.1016/j.chiabu.2016.10.008. Epub 2016 Nov 11.

PMID:
27842265
16.

The prospective usefulness of callous-unemotional traits and conduct disorder in predicting treatment engagement among detained girls.

Colins OF, Van Damme L, Fanti KA, Andershed H.

Eur Child Adolesc Psychiatry. 2017 Jan;26(1):75-85. doi: 10.1007/s00787-016-0869-7. Epub 2016 Jun 3.

17.

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.

Nanda K, Callahan R, Taylor D, Wang M, Agot K, Jenkins D, Van Damme L, Dorflinger L; FEM-PrEP Study Group.

Contraception. 2016 Jul;94(1):40-7. doi: 10.1016/j.contraception.2016.03.003. Epub 2016 Mar 10.

18.

Quality of life in relation to future mental health problems and offending: Testing the good lives model among detained girls.

Van Damme L, Hoeve M, Vermeiren R, Vanderplasschen W, Colins OF.

Law Hum Behav. 2016 Jun;40(3):285-94. doi: 10.1037/lhb0000177. Epub 2016 Feb 4.

PMID:
26844913
19.

Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.

Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, Malamatsho F, Odhiambo J, Skhosana J, Van Damme L.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):452-61. doi: 10.1097/QAI.0000000000000880.

PMID:
26536315
20.

Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.

Malahleha M, Ahmed K, Deese J, Nanda K, van Damme L, De Baetselier I, Burnett RJ.

J Med Case Rep. 2015 Sep 28;9:207. doi: 10.1186/s13256-015-0679-4.

21.

Injectable Progestin-Only Contraception is Associated With Increased Levels of Pro-Inflammatory Cytokines in the Female Genital Tract.

Deese J, Masson L, Miller W, Cohen M, Morrison C, Wang M, Ahmed K, Agot K, Crucitti T, Abdellati S, Van Damme L.

Am J Reprod Immunol. 2015 Oct;74(4):357-67. doi: 10.1111/aji.12415. Epub 2015 Jul 22.

PMID:
26202107
22.

Facilitators of adherence to the study pill in the FEM-PrEP clinical trial.

Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L.

PLoS One. 2015 Apr 13;10(4):e0125458. doi: 10.1371/journal.pone.0125458. eCollection 2015.

23.

Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV.

De Baetselier I, Menten J, Cuylaerts V, Ahmed K, Deese J, Van Damme L, Crucitti T.

PLoS One. 2015 Mar 23;10(3):e0120207. doi: 10.1371/journal.pone.0120207. eCollection 2015.

24.

The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, Skhosana J, Odhiambo J, Van Damme L.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-84. doi: 10.1097/QAI.0000000000000525.

PMID:
25761233
25.

Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.

Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N.

PLoS Med. 2015 Jan 22;12(1):e1001778. doi: 10.1371/journal.pmed.1001778. eCollection 2015 Jan.

26.

Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.

Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D; FEM-PrEP Study Group.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):196-203. doi: 10.1097/QAI.0000000000000413.

PMID:
25590272
27.

Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.

Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D, Van Damme L.

BMC Pharmacol Toxicol. 2014 Dec 24;15:77. doi: 10.1186/2050-6511-15-77.

28.

Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.

Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, Van Damme L; FEM-PrEP Study Group.

Contraception. 2015 Mar;91(3):248-52. doi: 10.1016/j.contraception.2014.10.008. Epub 2014 Oct 22.

PMID:
25459097
29.

Gender differences in psychiatric disorders and clusters of self-esteem among detained adolescents.

Van Damme L, Colins OF, Vanderplasschen W.

Psychiatry Res. 2014 Dec 30;220(3):991-7.

PMID:
25454118
30.

Girls' quality of life prior to detention in relation to psychiatric disorders, trauma exposure and socioeconomic status.

Van Damme L, Colins O, De Maeyer J, Vermeiren R, Vanderplasschen W.

Qual Life Res. 2015 Jun;24(6):1419-29. doi: 10.1007/s11136-014-0878-2. Epub 2014 Nov 28.

PMID:
25429824
31.

Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.

Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L; FEM-PrEP Study Group.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):555-63. doi: 10.1097/QAI.0000000000000362.

PMID:
25393942
32.

The future of multipurpose prevention technology product strategies: understanding the market in parallel with product development.

Romano JW, Van Damme L, Hillier S.

BJOG. 2014 Oct;121 Suppl 5:15-8. doi: 10.1111/1471-0528.12850. No abstract available.

33.

The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa.

Headley J, Lemons A, Corneli A, Agot K, Ahmed K, Wang M, Odhiambo J, Skhosana J, Tharaldson J, Van Damme L, MacQueen K; FEM-PrEP Study Group.

PLoS One. 2014 Sep 17;9(9):e106410. doi: 10.1371/journal.pone.0106410. eCollection 2014.

34.

FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.

Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Manongi R, Kapiga S, Kashuba A, Van Damme L; FEM-PrEP Study Group.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):324-31. doi: 10.1097/QAI.0000000000000158.

35.

Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.

Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba AD, Parker C, Lemons A, Malahleha M, Lombaard J, Van Damme L.

AIDS Behav. 2015 May;19(5):743-51. doi: 10.1007/s10461-014-0859-z.

36.

Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya.

Owino F, Mandala J, Ambia J, Agot K, Van Damme L.

Int Med Case Rep J. 2013 Nov 29;6:91-3. doi: 10.2147/IMCRJ.S52015. eCollection 2013.

37.

Intermediate vaginal flora and bacterial vaginosis are associated with the same factors: findings from an exploratory analysis among female sex workers in Africa and India.

Guédou FA, Van Damme L, Deese J, Crucitti T, Mirembe F, Solomon S, Becker M, Alary M.

Sex Transm Infect. 2014 Mar;90(2):161-4. doi: 10.1136/sextrans-2012-050896. Epub 2013 Nov 13.

PMID:
24226098
38.

The evolving design and methods for trials evaluating the safety of candidate vaginal microbicides: a systematic review.

Jespers V, Millwood IY, Poynten IM, Van Damme L, Kaldor JM.

Sex Transm Dis. 2013 Sep;40(9):729-36. doi: 10.1097/01.olq.0000431070.38601.03. Review.

PMID:
23945427
39.

Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial.

Guédou FA, Van Damme L, Deese J, Crucitti T, Becker M, Mirembe F, Solomon S, Alary M.

BMC Infect Dis. 2013 May 8;13:208. doi: 10.1186/1471-2334-13-208.

40.

Antiretroviral preexposure prophylaxis for HIV prevention.

Van Damme L, Corneli A.

N Engl J Med. 2013 Jan 3;368(1):84. doi: 10.1056/NEJMc1210464. No abstract available.

PMID:
23293792
41.

Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?

Adams JL, Sykes C, Menezes P, Prince HM, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):260-6. doi: 10.1097/QAI.0b013e3182794723.

42.

Current status of topical antiretroviral chemoprophylaxis.

Van Damme L, Szpir M.

Curr Opin HIV AIDS. 2012 Nov;7(6):520-5. doi: 10.1097/COH.0b013e3283582ca7. Review.

PMID:
22918449
43.

Preexposure prophylaxis for HIV infection among African women.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group.

N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.

44.

Intermediate vaginal flora is associated with HIV prevalence as strongly as bacterial vaginosis in a cross-sectional study of participants screened for a randomised controlled trial.

Guédou FA, Van Damme L, Mirembe F, Solomon S, Becker M, Deese J, Crucitti T, Alary M.

Sex Transm Infect. 2012 Nov;88(7):545-51. doi: 10.1136/sextrans-2011-050319. Epub 2012 May 24.

PMID:
22628663
45.

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.

AIDS. 2012 Apr 24;26(7):F13-9. doi: 10.1097/QAD.0b013e3283522272.

PMID:
22333749
46.

Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial.

Crucitti T, Taylor D, Beelaert G, Fransen K, Van Damme L.

Clin Vaccine Immunol. 2011 Sep;18(9):1480-5. doi: 10.1128/CVI.05069-11. Epub 2011 Jul 13.

47.

Predictors of pregnancy in microbicide trials.

Halpern V, Lie CC, Feldblum P, Van Damme L; Microbicide Research Group.

Contraception. 2011 May;83(5):436-40. doi: 10.1016/j.contraception.2010.08.018. Epub 2010 Oct 8.

PMID:
21477686
48.

HIV prevention in women: next steps.

Vermund SH, Van Damme L.

Science. 2011 Jan 21;331(6015):284. doi: 10.1126/science.331.6015.284-a. No abstract available.

PMID:
21252332
49.

Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a microbicide phase III clinical trial.

Crucitti T, Fransen K, Maharaj R, Tenywa T, Massinga Loembé M, Murugavel KG, Mendonca K, Abdellati S, Beelaert G, Van Damme L.

PLoS One. 2010 Oct 27;5(10):e13592. doi: 10.1371/journal.pone.0013592.

50.

Notes on the frequency of routinely collected and self-reported behavioral data in HIV prevention trials.

Taylor DJ, Lie CC, Weaver MA, Tolley E, Van Damme L, Halpern V, Feldblum P, Ogunsola F, Obunge O, Ramjee G, Alary M, Mirembe F.

AIDS Behav. 2011 Feb;15(2):389-95. doi: 10.1007/s10461-010-9822-9.

PMID:
20957424

Supplemental Content

Loading ...
Support Center